Efficacy and safety of periodontal initial therapy combined with intralesional betamethasone sodium phosphate injection under local anesthesia in managing erosive oral lichen planus: study protocol for a multi-center, split-mouth, randomized self-controlled trial Authors: Huiwen Chen, Liran Shi, Qianhui Shang, Zihao Wei, Qiaozhen Yang, Yining He, Chenxi Li, Zengtong Zhou, Guoyao Tang, Hongying Sun, Gulinuer Awuti, Zhongchen Song, Linjun Shi Published: 2025 ABSTRACT IntroductionErosive oral lichen planus (OLP) and periodontitis frequently coexist and may worsen each other. This study will evaluate the effectiveness and safety of combining periodontal initial therapy under local anesthesia with intralesional betamethasone sodium phosphate (BSP) injection in patients with erosive OLP, particularly in enhancing lesion healing.Methods and analysisThis is a multicenter, randomized, split-mouth, self-controlled trial. We will recruit 29 adults from five tertiary centers in China. Eligible participants are adults (aged ≥ 18 years) diagnosed with erosive gingival OLP accompanied by generalized periodontitis (stage II–IV). Within each participant, sides will be randomly allocated to a test side (periodontal initial therapy under local anesthesia plus intralesional BSP) and a control side (intralesional BSP alone). Independent outcome assessors and statisticians will be strictly blinded to ensure objectivity of the assessments. The follow-up will last 6 months, with assessments at the 2nd, 4th, 8th, 12th, and 24th weeks. The primary outcome is the reduction in erosive lesion size at the 12th week. Secondary outcomes will include the complete healing rate, OLP clinical severity scores, visual analog score of pain, periodontal parameters, and complications.DiscussionThis protocol introduces an innovative method for managing erosive OLP accompanied by periodontitis by integrating periodontal initial therapy under local anesthesia with corticosteroid injections. It aims to offer a more effective and patient-centric multidisciplinary treatment strategy. The utilization of local anesthetics will enhance patient comfort and optimize adherence. Findings will guide clinical practice and motivate mechanistic studies.Trial registrationThe trial has been registered on the Chinese Clinical Trial Registry (No. ChiCTR2400083728; registered on April 30, 2024) and on the U.S. National Institutes of Health Clinical Trials website (No. NCT06498180; registered on July 12, 2024).Protocol version: 1.0Version date: 01 September 2025.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-025-09340-5. Background Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa [1]. Clinically, OLP is classified into two types: non-erosive and erosive [2]. The chronic erosive lesions of OLP carry a risk of malignant transformation, leading the World Health Organization to classify it as a potentially malignant disorder [3]. A systematic review revealed that the pooled proportion of malignant transformation in OLP was 2.28% (95% CI, 1.49 to 3.20) [4]. The chronic inflammatory process is believed to drive this risk. Due to the enigmatic etiology and pathogenesis, effective interventions to delay disease progression or reverse its course are lacking [1, 5]. Current clinical management for erosive OLP primarily involves corticosteroids to manage symptoms [1, 2]. Among the available options, betamethasone sodium phosphate (BSP) is an advantageous choice due to its rapid onset of action and slower absorption to prolong the effect compared to other corticosteroids. Periodontitis is another highly prevalent chronic inflammatory disease, initiated by bacterial biofilms that lead to the progressive destruction of tooth-supporting tissues [6]. Affecting approximately 11% of the global population, it is a significant public health issue [7]. Crucially, some evidence indicated a bidirectional, mutually exacerbating relationship between OLP and periodontitis. The severe pain from erosive OLP compromises a patient’s ability to maintain oral hygiene, which contributes to the development and progression of periodontitis. In turn, the persistent periodontal inflammation creates a microenvironment that is understood to inhibit the healing of OLP lesions, thus establishing a vicious cycle [8, 9]. This establishes a clear rationale that plaque control and reduction of periodontal inflammation may alleviate the clinical symptoms of OLP and accelerate the healing of erosive lesions [10, 11]. However, a significant clinical barrier remains: conventional periodontal therapy, including scaling and debridement, is often too painful for patients with tender erosive lesions, leading to treatment refusal. Using local anesthesia offers a practical solution to overcome this pain barrier [12, 13]. Nevertheless, clinical trials evaluating the synergistic effect of periodontal therapy under local anesthesia combined with intralesional corticosteroids are currently lacking. Therefore, this study aims to conduct a multi-center, split-mouth, randomized self-controlled trial. We hypothesize that periodontal initial therapy under local anesthesia combined with intralesional BSP injection therapy will not only improve patient comfort during treatment but also enhance the healing of erosive mucosal lesions compared to intralesional BSP therapy alone. Methods Trial objectives The primary aim To evaluate the efficacy of periodontal initial treatment under local anesthesia combined with intralesional corticosteroids therapy in improving the clinical outcome of erosive OLP compared with intralesional corticosteroids therapy alone. Secondary aim Evaluation of the therapeutic safety of periodontal initial treatment under local anesthesia combined with intralesional corticosteroids therapy compared with conventional intralesional corticosteroids therapy for erosive OLP. Trial design This study is a multicenter, randomized, split-mouth, self-controlled clinical trial. The intervention (periodontal initial treatment) follows the current international standards for periodontitis treatment. The trial will not require additional invasive procedures beyond routine clinical visits. Patients or public involvement will not be involved in the design, conduct, or reporting of this trial. Using a randomized, split-mouth design, each participant’s oral cavity will be divided along the midline into a left and a right side. Through a computer-generated randomization, one side will be assigned as the test side and the other will subsequently be designated as the control side. The test side will receive periodontal initial therapy under local anesthesia combined with intralesional BSP. The control side will receive intralesional BSP alone. Follow-up will last 6 months. Assessments will occur at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. The primary endpoint of this study is set at the 12-week visit. Following the primary outcome assessment at the 12th week, the control side will then receive delayed periodontal initial treatment under local anesthesia for ethical reasons. Consequently, the period from the 12th week to the 24th week is defined as a prospective observational follow-up phase to assess long-term outcomes. Participants, interventions, and outcomes Trial setting A flowchart of the recruitment process is shown in Fig. 1 and Table 1. Twenty-nine participants with erosive OLP accompanied by stage II–IV periodontitis will be recruited from the Department of Oral Mucosal Diseases at the Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine (main center), Department of Stomatology at Shanghai Baoshan Hospital (sub-center I), Periodontal Disease Department of the First Affiliated Hospital of Xinjiang Medical University (sub-center II), Stomatology Hospital affiliated to Zhejiang University School of Medicine (sub-center III), and Department of Stomatology at Huashan Hospital (sub-center IV). Potential participants will be identified by the research team at each of the recruiting centers. Fig. 1Flowchart of the recruitment processTable 1Study design schedule during interviews for interventional experimentsTime pointStudy periodBaselineAllocationPost allocation− 14 days0 days2 weeks ± 3 days4 weeks ± 3 days8 weeks ± 7 days12 weeks ± 7 days24 weeks ± 7 daysEnrollment: Informed consent× Eligibility screen× Demographic characteristics× Systemic medical history× Medication history×Assessment: Periodontal examination (PD, CAL, GI, PLI)Φ××××× Oral mucosa examination× REU scoring system×××××× RHU scoring system×××××× The size of the erosion area (mm2)×××××× VAS of pain level (0–10)×××××× Complication×××××Histopathology: Gingival tissue biopsy*×Interventions: Topical BSP injection× Periodontal therapy combined with topical BSP injection under local anesthesia×Adverse event monitoring (Serious) adverse event×××× Concomitant medications××××PLI plaque index, PD probing depth, CAL clinical attachment loss, GI gingival index, REU reticulation/erythema/ulcer, RHU reticulation/hyperemia/ulceration, BSP betamethasone sodium phosphate, VAS visual analog scoreΦPD and CAL are measured in mm. GI and PLI are ordinal scores (e.g., 0–3)*The specific timing of the biopsy will be within 2 weeks of the screening assessment date, with enrolment determined by the the pathological diagnosisData are presented as mean ± standard deviation, unless otherwise specified. Variables with a skewed distribution are presented as median (interquartile range, IQR) Flowchart of the recruitment process Table 1Study design schedule during interviews for interventional experimentsTime pointStudy periodBaselineAllocationPost allocation− 14 days0 days2 weeks ± 3 days4 weeks ± 3 days8 weeks ± 7 days12 weeks ± 7 days24 weeks ± 7 daysEnrollment: Informed consent× Eligibility screen× Demographic characteristics× Systemic medical history× Medication history×Assessment: Periodontal examination (PD, CAL, GI, PLI)Φ××××× Oral mucosa examination× REU scoring system×××××× RHU scoring system×××××× The size of the erosion area (mm2)×××××× VAS of pain level (0–10)×××××× Complication×××××Histopathology: Gingival tissue biopsy*×Interventions: Topical BSP injection× Periodontal therapy combined with topical BSP injection under local anesthesia×Adverse event monitoring (Serious) adverse event×××× Concomitant medications××××PLI plaque index, PD probing depth, CAL clinical attachment loss, GI gingival index, REU reticulation/erythema/ulcer, RHU reticulation/hyperemia/ulceration, BSP betamethasone sodium phosphate, VAS visual analog scoreΦPD and CAL are measured in mm. GI and PLI are ordinal scores (e.g., 0–3)*The specific timing of the biopsy will be within 2 weeks of the screening assessment date, with enrolment determined by the the pathological diagnosisData are presented as mean ± standard deviation, unless otherwise specified. Variables with a skewed distribution are presented as median (interquartile range, IQR) Study design schedule during interviews for interventional experiments PLI plaque index, PD probing depth, CAL clinical attachment loss, GI gingival index, REU reticulation/erythema/ulcer, RHU reticulation/hyperemia/ulceration, BSP betamethasone sodium phosphate, VAS visual analog score ΦPD and CAL are measured in mm. GI and PLI are ordinal scores (e.g., 0–3) *The specific timing of the biopsy will be within 2 weeks of the screening assessment date, with enrolment determined by the the pathological diagnosis Data are presented as mean ± standard deviation, unless otherwise specified. Variables with a skewed distribution are presented as median (interquartile range, IQR) Screening overview and recruitment To achieve the target sample size, recruitment will occur at the outpatient clinics of all participating centers. During routine care, attending clinicians will identify potentially eligible patients and refer them to the site’s research team. Following this referral, a qualified clinical investigator, with full access to the participant’s complete medical and dental history, will confirm eligibility. Eligibility will be systematically assessed and documented to ensure each individual has a confirmed diagnosis of both bilateral erosive oral lichen planus and co-existing periodontitis and that they meet all inclusion and no exclusion criteria. After confirming all entry criteria, the investigator or a designated team member will formally enroll the participant, obtaining written informed consent prior to any randomization or trial-related procedures. The Coordinating Center will monitor enrollment numbers monthly, and a contingency plan will be activated if recruitment falls behind schedule. Inclusion criteria Patients ≥ 18 years of age.Presence of erosive OLP lasting > 2 months [1].Erosive OLP lesions are located bilaterally on the gingiva of the posterior teeth, buccal mucosa, or mucogingival junction.The severity of erosive OLP lesions is mild to moderate (single or multiple small erosive lesions; 3 mm ≤ longest diameter ≤ 10 mm; 9 mm2 ≤ total area of erosion ≤ 100 mm2) and the degree of bilateral erosive lesions is similar (the difference in the size of the erosion on both sides must not exceed ± 25%).In the area of erosive lesions, the plaque index ≥ 3, the calculus index ≥ 2, and the gingival index ≥ 2.Patients diagnosed with periodontitis (generalized, stage II–IV) [6]. Patients ≥ 18 years of age. Patients ≥ 18 years of age. Presence of erosive OLP lasting > 2 months [1]. Presence of erosive OLP lasting > 2 months [1]. Erosive OLP lesions are located bilaterally on the gingiva of the posterior teeth, buccal mucosa, or mucogingival junction. Erosive OLP lesions are located bilaterally on the gingiva of the posterior teeth, buccal mucosa, or mucogingival junction. The severity of erosive OLP lesions is mild to moderate (single or multiple small erosive lesions; 3 mm ≤ longest diameter ≤ 10 mm; 9 mm2 ≤ total area of erosion ≤ 100 mm2) and the degree of bilateral erosive lesions is similar (the difference in the size of the erosion on both sides must not exceed ± 25%). The severity of erosive OLP lesions is mild to moderate (single or multiple small erosive lesions; 3 mm ≤ longest diameter ≤ 10 mm; 9 mm2 ≤ total area of erosion ≤ 100 mm2) and the degree of bilateral erosive lesions is similar (the difference in the size of the erosion on both sides must not exceed ± 25%). In the area of erosive lesions, the plaque index ≥ 3, the calculus index ≥ 2, and the gingival index ≥ 2. In the area of erosive lesions, the plaque index ≥ 3, the calculus index ≥ 2, and the gingival index ≥ 2. Patients diagnosed with periodontitis (generalized, stage II–IV) [6]. Patients diagnosed with periodontitis (generalized, stage II–IV) [6]. Exclusion criteria Pregnant women or women planning pregnancy during the study.Hematologic disorders with a quantitative or qualitative deficit of leucocytes.Received periodontal initial treatment within the past 6 months.History of allergy to articaine.Contraindication to glucocorticoids.Patients with erosion lesions due to trauma or chemical irritation.Patients with erosion lesions due to the presence of residual roots or crowns.Patients with mental disorders who are difficult to cooperate with treatment.Patients with other serious oral mucosal diseases.Patients with a known allergy to iodine or any iodine-containing products.Glucocorticosteroids use within the past 1 week. Pregnant women or women planning pregnancy during the study. Pregnant women or women planning pregnancy during the study. Hematologic disorders with a quantitative or qualitative deficit of leucocytes. Hematologic disorders with a quantitative or qualitative deficit of leucocytes. Received periodontal initial treatment within the past 6 months. Received periodontal initial treatment within the past 6 months. History of allergy to articaine. History of allergy to articaine. Contraindication to glucocorticoids. Contraindication to glucocorticoids. Patients with erosion lesions due to trauma or chemical irritation. Patients with erosion lesions due to trauma or chemical irritation. Patients with erosion lesions due to the presence of residual roots or crowns. Patients with erosion lesions due to the presence of residual roots or crowns. Patients with mental disorders who are difficult to cooperate with treatment. Patients with mental disorders who are difficult to cooperate with treatment. Patients with other serious oral mucosal diseases. Patients with other serious oral mucosal diseases. Patients with a known allergy to iodine or any iodine-containing products. Patients with a known allergy to iodine or any iodine-containing products. Glucocorticosteroids use within the past 1 week. Glucocorticosteroids use within the past 1 week. Subjects who meet the inclusion and exclusion criteria will be invited to participate in the study and will be fully informed about the purposes, risks, and potential benefits of the present clinical trial. Removal criteria Failure to meet essential inclusion criteria.The participant did not receive the assigned intervention.Absence of data for analysis following randomization. Failure to meet essential inclusion criteria. Failure to meet essential inclusion criteria. The participant did not receive the assigned intervention. The participant did not receive the assigned intervention. Absence of data for analysis following randomization. Absence of data for analysis following randomization. Withdrawal criteria Participants are entitled to withdraw at any time. No further special observation or treatment will be required after withdrawal. The following list provides examples of potential reasons and circumstances that could result in withdrawal from the study:Based on the best interests of the patient.Failure to meet eligibility criteria (including overlooking relevant factors during screening or new circumstances arising during the course of the trial that make enrollment inappropriate).Obvious protocol violations or deviations.Failure to complete treatment and follow-up as prescribed.The participant is unable to continue in the trial due to an adverse event.Inability to continue following the protocol (e.g., participant moves to another city).Patient withdraws at his/her own discretion.Loss of follow-up. Based on the best interests of the patient. Based on the best interests of the patient. Failure to meet eligibility criteria (including overlooking relevant factors during screening or new circumstances arising during the course of the trial that make enrollment inappropriate). Failure to meet eligibility criteria (including overlooking relevant factors during screening or new circumstances arising during the course of the trial that make enrollment inappropriate). Obvious protocol violations or deviations. Obvious protocol violations or deviations. Failure to complete treatment and follow-up as prescribed. Failure to complete treatment and follow-up as prescribed. The participant is unable to continue in the trial due to an adverse event. The participant is unable to continue in the trial due to an adverse event. Inability to continue following the protocol (e.g., participant moves to another city). Inability to continue following the protocol (e.g., participant moves to another city). Patient withdraws at his/her own discretion. Patient withdraws at his/her own discretion. Loss of follow-up. Loss of follow-up. Data handling for withdrawn participants The reasons, the date of the last treatment completed, and any valuable data collected up to the date of withdrawal will be recorded. If participants withdraw from this study due to adverse events (AEs), the researcher will arrange follow-up until the AEs are properly handled. The primary analysis will follow an intention-to-treat (ITT) principle with multiple imputation for missing data. A per-protocol set (PPS) will also be conducted as a sensitivity analysis. No replacement participants will be recruited. Participants management To enhance participant compliance with the study, several strategies will be implemented. During the informed consent process, the full study timeline, the schedule of follow-up visits, and the importance of completing the study will be thoroughly explained to each participant. A dedicated study coordinator is assigned, and participants will be provided with direct contact information to address any questions or concerns and to facilitate appointment scheduling. Reminder telephone calls or text messages will be made 1 day prior to each scheduled visit. To accommodate participants’ personal schedules and minimize their burden, flexible scheduling for follow-up appointments will be offered whenever possible. Trial intervention The test side will be treated with intralesional BSP injection and periodontal initial treatment under local anesthesia, while the control side will be treated with intralesional BSP injection alone. For ethical reasons, the control side will undergo full-mouth periodontal initial therapy at the end of the primary endpoint assessment. Intralesional BSP procedure All participants will receive intralesional BSP injections following their baseline evaluation. Prior to the injection, the mucosal surface surrounding the lesion will be disinfected with an iodine tincture to minimize the risk of infection and ensure aseptic conditions during the procedure. As shown in Fig. 2, each erosive lesion will be treated with a single submucosal injection of 1.4 mg (0.35 mL) betamethasone (BSP; Sinopharm Group Rongsheng Pharmaceutical Co., Ltd., China). This evidence-based dosage, equivalent to 7 mg of triamcinolone acetonide, is based on the protocol by Liu et al. [14]. Using a 5-mL syringe with a 25-gauge needle, the injection will be administered from the adjacent non-erosive mucosa at a 45-degree angle. The needle will be advanced to a submucosal depth sufficient to raise a small wheal. Aspiration will be performed to prevent intravascular injection, and sterile gauze will be applied to the site post-injection to control bleeding. After the injection, participants will be observed closely for 20 min to monitor for any immediate adverse reactions (e.g., swelling, pain, systemic symptoms).Fig. 2Each erosive lesion will be treated with a single submucosal injection Each erosive lesion will be treated with a single submucosal injection Periodontal initial therapy A periodontist with extensive clinical experience will perform periodontal initial therapy in the posterior teeth corresponding to erosive mucosal lesions. Before the periodontal therapy, a 0.12% chlorhexidine rinse will be applied for intraoral antisepsis. The procedure will include full-mouth scaling and root planning by ultrasonic instruments (EMS, Master® Piezon 700, Swiss) and manual Gracey curettes (Hu-Friedy, Chicago, USA) under local anesthesia (Primacaine™ adrenaline 1/100,000, Produits Dentaires Pierre Rolland, France). Each tooth that has undergone scaling will be polished with a rubber cup and polishing paste [15]. All test sides will undergo periodontal initial treatment on the day of intervention, followed by therapy for oral mucosal lesions. Oral hygiene education and adjuncts All participants will receive thorough professional oral hygiene education with demonstrations (manual toothbrushes, dental floss, or interdental brushes). We will recommend routine rinsing with a 1% sodium bicarbonate solution throughout the study period. To ensure consistency in the study’s outcomes, they will also be instructed to avoid the use of other systemic medications that could interfere with the treatment protocol. Training and calibration To ensure procedural consistency across all participating centers, all investigators underwent a formal training and calibration process before the study commenced. The physicians responsible for periodontal measurements and periodontal initial treatment are required to be experienced periodontists. Before the study commences, all participating periodontists from each center will be required to participate in an off-line in-person training program organized by the principal investigator. The training curriculum will cover a detailed review of the study protocol and an explanation of the operational techniques for periodontal scaling and root planning. A standardized procedural checklist will be distributed to ensure high consistency in every step across all periodontists and centers. This checklist will detail critical parameters, including the specific standards and examination methods for periodontal measurements, specific ultrasonic scaler power settings, correct curette angulation, and appropriate scaling force. Furthermore, they will perform calibration exercises on non-study patients under the supervision of a calibrated “gold standard” examiner. Similarly, clinicians responsible for administering the intralesional injections were also calibrated to ensure uniform technique; the specific details of their calibration protocol are described in the “Trial intervention” section. All assessors will also undergo calibration exercises to standardize their evaluation methods. Inter-rater reliability will be evaluated using the Intraclass correlation coefficient (ICC) for continuous data and the weighted Kappa statistic for ordinal scores. A pre-specified high level of agreement (e.g., ICC > 0.80, Kappa > 0.80) must be achieved. Researchers responsible for oral hygiene instruction will receive standardized training in oral hygiene practices, including oral hygiene instructions, the use of plaque disclosing agents, and demonstrations of brushing, flossing, and interdental brushing techniques. Baseline data collection Demographics: Date of birth, sex, education level, and a detailed smoking history.Systemic medical history: The presence of any known systemic conditions. For participants with a history of hypertension, resting blood pressure (systolic and diastolic) will be measured and recorded. For participants with a history of diabetes, recent laboratory values for fasting blood glucose and/or glycated hemoglobin will be documented.Concomitant medications: All prescription and over-the-counter drugs and supplements, with dose and frequency. Demographics: Date of birth, sex, education level, and a detailed smoking history. Demographics: Date of birth, sex, education level, and a detailed smoking history. Systemic medical history: The presence of any known systemic conditions. For participants with a history of hypertension, resting blood pressure (systolic and diastolic) will be measured and recorded. For participants with a history of diabetes, recent laboratory values for fasting blood glucose and/or glycated hemoglobin will be documented. Systemic medical history: The presence of any known systemic conditions. For participants with a history of hypertension, resting blood pressure (systolic and diastolic) will be measured and recorded. For participants with a history of diabetes, recent laboratory values for fasting blood glucose and/or glycated hemoglobin will be documented. Concomitant medications: All prescription and over-the-counter drugs and supplements, with dose and frequency. Concomitant medications: All prescription and over-the-counter drugs and supplements, with dose and frequency. Outcome measures Outcome measures will be conducted at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. To ensure consistency and reliability, all assessments at each time point will be conducted by two independent, calibrated central assessors who are blinded to treatment allocation and are not involved in any clinical aspect of the trial. Primary outcome measure (assessed at 12th week) The primary outcome measure is the reduction in the size of the erosion area (mm2) of the lesion after 3 months of intervention, compared to the control side. The area of OLP erosion will be quantified using a digital intraoral scanner (3Shape TRIOS 4, 3Shape, Copenhagen, Denmark). The scanner will be calibrated according to the manufacturer’s guidelines. Secondary outcome measures (assessed up to 12th week) Completely healing rate of erosive lesionsThe healing rates of erosive lesions will be compared, evaluated as a binary variable (healed/not healed), at the 2nd, 4th, 8th, 12th, and 24th week post-intervention.Change in painThe absolute difference in the visual analogue scale (VAS) pain score from baseline will be evaluated at the 2nd, 4th, 8th, 12th, and 24th week post-intervention.The VAS for pain is a 10 cm line with “no pain” (0) at one end and “worst imaginable pain” (10) at the other. The patient marks a point on the line that represents their pain intensity, and the pain level is measured based on the distance from the “no pain” end to the mark, providing a quantitative assessment of pain.Change in OLP clinical severity scoreThe absolute difference in the clinical severity score for OLP (e.g., reticulation/erythema/ulcer (RHU)/reticulation/hyperemia/ulceration (RHU) score) from baseline will be evaluated at the 2nd, 4th, 8th, 12th, and 24th week post-intervention.Both the REU scoring system [16] and RHU scoring system [17] were employed in the present study. These scoring systems typically take into account several key factors, such as lesion size, clinical appearance, symptom severity, lesion distribution. The scores from these components are typically combined to provide an overall score.For REU scoring system, lesion severity at each site will be assessed by scoring reticular/hyperkeratotic, erosive/erythematous, and ulcerative lesions using specific criteria: Reticular/hyperkeratotic changes will be rated as 0 (absence of white striations) or 1 (presence of white striations or keratotic papules). Erosive/erythematous lesions will be graded on a 0–3 scale based on the area involved (0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2). Ulcerative lesions will also be evaluated on a 0–3 scale depending on lesion size (0 = no lesion, 1 = less than 1 cm2, 2 = 1–3 cm2, 3 = more than 3 cm2). The scores for the three clinical features were calculated by summing the individual scores across each site: reticular score (ΣR), erythema score (ΣE), and ulcerative score (ΣU). A composite REU score was determined using a weighted formula: REU = ΣR + Σ (E × 1.5) + Σ (U × 2.0) (Table 2). Table 2REU scoring systemSiteReticular area (R)Erythematous area (E)Ulcerative area (U)(Right/left) buccal mucosa0101230123(Right/left) maxillary gingiva0101230123(Right/left) mandibular gingiva0101230123TotalREU=ΣR + Σ(E × 1.5) + Σ(U × 2.0)Reticular area: 0 = absence of white striations; 1= presence of white striations or keratotic papulesErythematous area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2Ulcerative area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2The RHU scoring system is a further improvement on the REU system (Table 3). The extent of reticular lesions is categorized into three levels, scored from 0 to 2: a score of 0 indicates the absence of reticulation in the area, a score of 1 denotes reticulation affecting less than 50% of the mucosal surface, and a score of 2 signifies reticulation covering 50% or more of the surface. Lesions involving erythema/hyperemia and erosion/ulceration are quantified in square centimeters to ensure sensitivity in detecting even minor changes. Table 3RHU scoring systemSiteReticulationa(0: none;1: <50%; 2: ≥50%)Hyperemia/erythemabArea: ( )×( ) cm2Erosion/ulcerationbArea: ( )×( ) cm2(Right/left) buccal mucosa(Right/left) maxillary gingiva (including vestibular sulcus)(Right/left) mandibular gingiva (including vestibular sulcus)Totalc ( )*1 ( )*1.5 ( )*2aWhite reticulation/patches are classified according to the proportion of their involved area to the total area of each part. If there is no white striations, the value is “0”; If the involved area is <50% of the total area of the part, the value is “1”; If the involved area is greater than or equal to 50% of the total area of the part, assign a value of “2”bArea of hyperemia/erythema and erosion/ulceration are record directlycIn statistical analysis, it is planned to add up the area of each part and weight them separatelyRHU = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2The overall score is determined by assigning different weights to the scores of reticulations, hyperemia/erythema, and erosion/ulceration. The formula used is: RHU scoring system total score = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2.Changes in periodontal parametersThe change from baseline in key periodontal clinical parameters, which include plaque index (PLI), probing depth (PD), clinical attachment loss (CAL), and gingival index (GI), at teeth adjacent to mucosal lesions will be assessed at the 4th, 8th, 12th, and 24th week post-intervention.The Silness and Löe PLI method will be applied [18]. This method utilizes a four-point scoring system: Score 0 indicates no visible plaque; Score 1 refers to a thin film of plaque detectable only with a probe; Score 2 represents a moderate amount of plaque visible to the naked eye; and Score 3 indicates a large accumulation of plaque that covers the gingival margin and adjacent tooth surfaces. The scores from all examined tooth surfaces are averaged to yield a final PLI score. For the GI, the Löe and Silness method will be applied [19]. The GI is typically scored on a scale of 0 to 3: Score 0 means normal gingiva; Score 1 means slight changes in color (redness) and mild swelling, but no bleeding on probing; Score 2 means redness, swelling, and glazing of the gingiva, with bleeding on probing or gentle manipulation; and Score 3 means marked redness, swelling, and ulceration, often accompanied by spontaneous bleeding.PD and CAL will be measured at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a calibrated periodontal probe (UNC-15, Hu-Friedy, Chicago, IL, USA).Incidence of complicationsThe frequency of any complications will be recorded at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. Completely healing rate of erosive lesionsThe healing rates of erosive lesions will be compared, evaluated as a binary variable (healed/not healed), at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. Completely healing rate of erosive lesions The healing rates of erosive lesions will be compared, evaluated as a binary variable (healed/not healed), at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. Change in painThe absolute difference in the visual analogue scale (VAS) pain score from baseline will be evaluated at the 2nd, 4th, 8th, 12th, and 24th week post-intervention.The VAS for pain is a 10 cm line with “no pain” (0) at one end and “worst imaginable pain” (10) at the other. The patient marks a point on the line that represents their pain intensity, and the pain level is measured based on the distance from the “no pain” end to the mark, providing a quantitative assessment of pain. Change in pain The absolute difference in the visual analogue scale (VAS) pain score from baseline will be evaluated at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. The VAS for pain is a 10 cm line with “no pain” (0) at one end and “worst imaginable pain” (10) at the other. The patient marks a point on the line that represents their pain intensity, and the pain level is measured based on the distance from the “no pain” end to the mark, providing a quantitative assessment of pain. Change in OLP clinical severity scoreThe absolute difference in the clinical severity score for OLP (e.g., reticulation/erythema/ulcer (RHU)/reticulation/hyperemia/ulceration (RHU) score) from baseline will be evaluated at the 2nd, 4th, 8th, 12th, and 24th week post-intervention.Both the REU scoring system [16] and RHU scoring system [17] were employed in the present study. These scoring systems typically take into account several key factors, such as lesion size, clinical appearance, symptom severity, lesion distribution. The scores from these components are typically combined to provide an overall score.For REU scoring system, lesion severity at each site will be assessed by scoring reticular/hyperkeratotic, erosive/erythematous, and ulcerative lesions using specific criteria: Reticular/hyperkeratotic changes will be rated as 0 (absence of white striations) or 1 (presence of white striations or keratotic papules). Erosive/erythematous lesions will be graded on a 0–3 scale based on the area involved (0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2). Ulcerative lesions will also be evaluated on a 0–3 scale depending on lesion size (0 = no lesion, 1 = less than 1 cm2, 2 = 1–3 cm2, 3 = more than 3 cm2). The scores for the three clinical features were calculated by summing the individual scores across each site: reticular score (ΣR), erythema score (ΣE), and ulcerative score (ΣU). A composite REU score was determined using a weighted formula: REU = ΣR + Σ (E × 1.5) + Σ (U × 2.0) (Table 2). Table 2REU scoring systemSiteReticular area (R)Erythematous area (E)Ulcerative area (U)(Right/left) buccal mucosa0101230123(Right/left) maxillary gingiva0101230123(Right/left) mandibular gingiva0101230123TotalREU=ΣR + Σ(E × 1.5) + Σ(U × 2.0)Reticular area: 0 = absence of white striations; 1= presence of white striations or keratotic papulesErythematous area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2Ulcerative area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2The RHU scoring system is a further improvement on the REU system (Table 3). The extent of reticular lesions is categorized into three levels, scored from 0 to 2: a score of 0 indicates the absence of reticulation in the area, a score of 1 denotes reticulation affecting less than 50% of the mucosal surface, and a score of 2 signifies reticulation covering 50% or more of the surface. Lesions involving erythema/hyperemia and erosion/ulceration are quantified in square centimeters to ensure sensitivity in detecting even minor changes. Table 3RHU scoring systemSiteReticulationa(0: none;1: <50%; 2: ≥50%)Hyperemia/erythemabArea: ( )×( ) cm2Erosion/ulcerationbArea: ( )×( ) cm2(Right/left) buccal mucosa(Right/left) maxillary gingiva (including vestibular sulcus)(Right/left) mandibular gingiva (including vestibular sulcus)Totalc ( )*1 ( )*1.5 ( )*2aWhite reticulation/patches are classified according to the proportion of their involved area to the total area of each part. If there is no white striations, the value is “0”; If the involved area is <50% of the total area of the part, the value is “1”; If the involved area is greater than or equal to 50% of the total area of the part, assign a value of “2”bArea of hyperemia/erythema and erosion/ulceration are record directlycIn statistical analysis, it is planned to add up the area of each part and weight them separatelyRHU = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2The overall score is determined by assigning different weights to the scores of reticulations, hyperemia/erythema, and erosion/ulceration. The formula used is: RHU scoring system total score = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2. Change in OLP clinical severity score The absolute difference in the clinical severity score for OLP (e.g., reticulation/erythema/ulcer (RHU)/reticulation/hyperemia/ulceration (RHU) score) from baseline will be evaluated at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. Both the REU scoring system [16] and RHU scoring system [17] were employed in the present study. These scoring systems typically take into account several key factors, such as lesion size, clinical appearance, symptom severity, lesion distribution. The scores from these components are typically combined to provide an overall score. For REU scoring system, lesion severity at each site will be assessed by scoring reticular/hyperkeratotic, erosive/erythematous, and ulcerative lesions using specific criteria: Reticular/hyperkeratotic changes will be rated as 0 (absence of white striations) or 1 (presence of white striations or keratotic papules). Erosive/erythematous lesions will be graded on a 0–3 scale based on the area involved (0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2). Ulcerative lesions will also be evaluated on a 0–3 scale depending on lesion size (0 = no lesion, 1 = less than 1 cm2, 2 = 1–3 cm2, 3 = more than 3 cm2). The scores for the three clinical features were calculated by summing the individual scores across each site: reticular score (ΣR), erythema score (ΣE), and ulcerative score (ΣU). A composite REU score was determined using a weighted formula: REU = ΣR + Σ (E × 1.5) + Σ (U × 2.0) (Table 2). Table 2REU scoring systemSiteReticular area (R)Erythematous area (E)Ulcerative area (U)(Right/left) buccal mucosa0101230123(Right/left) maxillary gingiva0101230123(Right/left) mandibular gingiva0101230123TotalREU=ΣR + Σ(E × 1.5) + Σ(U × 2.0)Reticular area: 0 = absence of white striations; 1= presence of white striations or keratotic papulesErythematous area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2Ulcerative area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2 Table 2REU scoring systemSiteReticular area (R)Erythematous area (E)Ulcerative area (U)(Right/left) buccal mucosa0101230123(Right/left) maxillary gingiva0101230123(Right/left) mandibular gingiva0101230123TotalREU=ΣR + Σ(E × 1.5) + Σ(U × 2.0)Reticular area: 0 = absence of white striations; 1= presence of white striations or keratotic papulesErythematous area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2Ulcerative area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2 REU scoring system REU=ΣR + Σ(E × 1.5) + Σ(U × 2.0) Reticular area: 0 = absence of white striations; 1= presence of white striations or keratotic papules Erythematous area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2 Ulcerative area: 0 = no lesion, 1 = area less than 1 cm2, 2 = area between 1 and 3 cm2, 3 = area larger than 3 cm2 The RHU scoring system is a further improvement on the REU system (Table 3). The extent of reticular lesions is categorized into three levels, scored from 0 to 2: a score of 0 indicates the absence of reticulation in the area, a score of 1 denotes reticulation affecting less than 50% of the mucosal surface, and a score of 2 signifies reticulation covering 50% or more of the surface. Lesions involving erythema/hyperemia and erosion/ulceration are quantified in square centimeters to ensure sensitivity in detecting even minor changes. Table 3RHU scoring systemSiteReticulationa(0: none;1: <50%; 2: ≥50%)Hyperemia/erythemabArea: ( )×( ) cm2Erosion/ulcerationbArea: ( )×( ) cm2(Right/left) buccal mucosa(Right/left) maxillary gingiva (including vestibular sulcus)(Right/left) mandibular gingiva (including vestibular sulcus)Totalc ( )*1 ( )*1.5 ( )*2aWhite reticulation/patches are classified according to the proportion of their involved area to the total area of each part. If there is no white striations, the value is “0”; If the involved area is <50% of the total area of the part, the value is “1”; If the involved area is greater than or equal to 50% of the total area of the part, assign a value of “2”bArea of hyperemia/erythema and erosion/ulceration are record directlycIn statistical analysis, it is planned to add up the area of each part and weight them separatelyRHU = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2 Table 3RHU scoring systemSiteReticulationa(0: none;1: <50%; 2: ≥50%)Hyperemia/erythemabArea: ( )×( ) cm2Erosion/ulcerationbArea: ( )×( ) cm2(Right/left) buccal mucosa(Right/left) maxillary gingiva (including vestibular sulcus)(Right/left) mandibular gingiva (including vestibular sulcus)Totalc ( )*1 ( )*1.5 ( )*2aWhite reticulation/patches are classified according to the proportion of their involved area to the total area of each part. If there is no white striations, the value is “0”; If the involved area is <50% of the total area of the part, the value is “1”; If the involved area is greater than or equal to 50% of the total area of the part, assign a value of “2”bArea of hyperemia/erythema and erosion/ulceration are record directlycIn statistical analysis, it is planned to add up the area of each part and weight them separatelyRHU = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2 RHU scoring system aWhite reticulation/patches are classified according to the proportion of their involved area to the total area of each part. If there is no white striations, the value is “0”; If the involved area is <50% of the total area of the part, the value is “1”; If the involved area is greater than or equal to 50% of the total area of the part, assign a value of “2” bArea of hyperemia/erythema and erosion/ulceration are record directly cIn statistical analysis, it is planned to add up the area of each part and weight them separately RHU = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2 The overall score is determined by assigning different weights to the scores of reticulations, hyperemia/erythema, and erosion/ulceration. The formula used is: RHU scoring system total score = R (reticulation score) × 1 + H (hyperemia score) × 1.5 + U (erosion score) × 2. Changes in periodontal parametersThe change from baseline in key periodontal clinical parameters, which include plaque index (PLI), probing depth (PD), clinical attachment loss (CAL), and gingival index (GI), at teeth adjacent to mucosal lesions will be assessed at the 4th, 8th, 12th, and 24th week post-intervention.The Silness and Löe PLI method will be applied [18]. This method utilizes a four-point scoring system: Score 0 indicates no visible plaque; Score 1 refers to a thin film of plaque detectable only with a probe; Score 2 represents a moderate amount of plaque visible to the naked eye; and Score 3 indicates a large accumulation of plaque that covers the gingival margin and adjacent tooth surfaces. The scores from all examined tooth surfaces are averaged to yield a final PLI score. For the GI, the Löe and Silness method will be applied [19]. The GI is typically scored on a scale of 0 to 3: Score 0 means normal gingiva; Score 1 means slight changes in color (redness) and mild swelling, but no bleeding on probing; Score 2 means redness, swelling, and glazing of the gingiva, with bleeding on probing or gentle manipulation; and Score 3 means marked redness, swelling, and ulceration, often accompanied by spontaneous bleeding.PD and CAL will be measured at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a calibrated periodontal probe (UNC-15, Hu-Friedy, Chicago, IL, USA). Changes in periodontal parameters The change from baseline in key periodontal clinical parameters, which include plaque index (PLI), probing depth (PD), clinical attachment loss (CAL), and gingival index (GI), at teeth adjacent to mucosal lesions will be assessed at the 4th, 8th, 12th, and 24th week post-intervention. The Silness and Löe PLI method will be applied [18]. This method utilizes a four-point scoring system: Score 0 indicates no visible plaque; Score 1 refers to a thin film of plaque detectable only with a probe; Score 2 represents a moderate amount of plaque visible to the naked eye; and Score 3 indicates a large accumulation of plaque that covers the gingival margin and adjacent tooth surfaces. The scores from all examined tooth surfaces are averaged to yield a final PLI score. For the GI, the Löe and Silness method will be applied [19]. The GI is typically scored on a scale of 0 to 3: Score 0 means normal gingiva; Score 1 means slight changes in color (redness) and mild swelling, but no bleeding on probing; Score 2 means redness, swelling, and glazing of the gingiva, with bleeding on probing or gentle manipulation; and Score 3 means marked redness, swelling, and ulceration, often accompanied by spontaneous bleeding. PD and CAL will be measured at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) using a calibrated periodontal probe (UNC-15, Hu-Friedy, Chicago, IL, USA). Incidence of complicationsThe frequency of any complications will be recorded at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. Incidence of complications The frequency of any complications will be recorded at the 2nd, 4th, 8th, 12th, and 24th week post-intervention. Exploratory outcomes (observational follow-up phase: 12th to 24th week) Therapeutic response of the control side:The change in key outcome measures (the size of the erosion area, REU/RHU scores, VAS, periodontal clinical parameters) on the original control side will be calculated using the 12-week assessment as the new baseline and the 24-week assessment as the endpoint, following the administration of delayed periodontal therapy.Durability of the test side:The stability of the treatment effect on the original test side will be evaluated by tracking changes in the same outcome measures between the 12th week and the 24th week, including the incidence of lesion recurrence.Long-term safety:The incidence of any new complications occurring in either group during this period will be recorded. Therapeutic response of the control side:The change in key outcome measures (the size of the erosion area, REU/RHU scores, VAS, periodontal clinical parameters) on the original control side will be calculated using the 12-week assessment as the new baseline and the 24-week assessment as the endpoint, following the administration of delayed periodontal therapy. Therapeutic response of the control side: The change in key outcome measures (the size of the erosion area, REU/RHU scores, VAS, periodontal clinical parameters) on the original control side will be calculated using the 12-week assessment as the new baseline and the 24-week assessment as the endpoint, following the administration of delayed periodontal therapy. Durability of the test side:The stability of the treatment effect on the original test side will be evaluated by tracking changes in the same outcome measures between the 12th week and the 24th week, including the incidence of lesion recurrence. Durability of the test side: The stability of the treatment effect on the original test side will be evaluated by tracking changes in the same outcome measures between the 12th week and the 24th week, including the incidence of lesion recurrence. Long-term safety:The incidence of any new complications occurring in either group during this period will be recorded. Long-term safety: The incidence of any new complications occurring in either group during this period will be recorded. Harms definition The safety of all participants is paramount. A comprehensive plan is in place for the monitoring, documentation, and management of all AEs. AE monitoring At each study visit, the investigator will proactively question participants about any potential AEs and perform clinical examinations. All AEs, whether reported by the participant or observed by the study staff, will be documented. Based on the interventions, potential AEs to be monitored include, but are not limited to: related to intralesional BSP injections (pain, swelling, bruising, or hemorrhage at the injection site; secondary infection; mucosal/submucosal atrophy; hypopigmentation or hyperpigmentation; sterile abscess; tissue necrosis); related to periodontal initial therapy (post-operative pain or soreness; root/tooth hypersensitivity; gingival bleeding; localized gingival swelling); and related to local anesthetics (allergic reactions; transient syncope or dizziness). Grading and causality The severity of each AE will be graded by the investigator according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) v6.0 criteria. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting age- appropriate instrumental ADL*.Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL**.Grade 4: Life-threatening consequences; urgent intervention is indicated.Grade 5: Death related to AE. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting age- appropriate instrumental ADL*. Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting age- appropriate instrumental ADL*. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL**. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL**. Grade 4: Life-threatening consequences; urgent intervention is indicated. Grade 4: Life-threatening consequences; urgent intervention is indicated. Grade 5: Death related to AE. Grade 5: Death related to AE. *Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. **Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications. The investigator will assess the potential relationship between each AE and the study intervention. The causality will be categorized using the following 5-point scale: Definite: The AE is clearly related to the intervention, cannot be explained by the participant’s underlying condition or other external factors, and follows a known response pattern to the intervention.Probable: The AE is likely related to the intervention, with a reasonable time sequence, and alternative causes are less likely.Possible: The AE may be related to the intervention, but it could also be attributed to other plausible causes.Unlikely: The AE is doubtfully related to the intervention. Other factors are a more probable cause.Unrelated: The event is clearly not related to the intervention. Definite: The AE is clearly related to the intervention, cannot be explained by the participant’s underlying condition or other external factors, and follows a known response pattern to the intervention. Definite: The AE is clearly related to the intervention, cannot be explained by the participant’s underlying condition or other external factors, and follows a known response pattern to the intervention. Probable: The AE is likely related to the intervention, with a reasonable time sequence, and alternative causes are less likely. Probable: The AE is likely related to the intervention, with a reasonable time sequence, and alternative causes are less likely. Possible: The AE may be related to the intervention, but it could also be attributed to other plausible causes. Possible: The AE may be related to the intervention, but it could also be attributed to other plausible causes. Unlikely: The AE is doubtfully related to the intervention. Other factors are a more probable cause. Unlikely: The AE is doubtfully related to the intervention. Other factors are a more probable cause. Unrelated: The event is clearly not related to the intervention. Unrelated: The event is clearly not related to the intervention. Serious adverse events (SAEs) An SAE will be any event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. Investigators will report SAEs to the Institutional Review Board/Ethics Committee (IRB/EC) within 24 h of awareness, followed by a detailed report. Management and stopping rules The investigator will ensure that any participant experiencing an AE receives appropriate medical care until the event resolves or stabilizes. Management may include observation, symptomatic treatment, or withdrawal from the study. We will withdraw individual participants for unacceptable AEs. The investigator, in consultation with the IRB/EC, may pause or terminate the study if SAE rates are unexpectedly high or if new information changes the risk-benefit profile. Sample size The sample size for this multi-center, split-mouth, randomized self-controlled trial was calculated based on its primary endpoint: the reduction in the oral erosion lesion area. The primary hypothesis of this study is directional (one-sided), as we aim to test if combined therapy is superior to monotherapy. According to previous literature [11], the mean reduction in the oral erosion lesion area with glucocorticoid local injections alone was 10.3 ± 13.2 mm2, while the mean reduction with periodontal initial therapy combined with glucocorticoid local injections was 19.1 ± 12.8 mm2. Using PASS 15.0 statistical software (NCSS LLC, Kaysville, UT, USA) for analysis, with a Type I error α of 0.025 and a power (1-β) of 0.8 (one-sided), and setting Δ = 0, the required sample size was determined to be 23 participants. To account for a potential 20% dropout rate, the final target enrollment was set to 29 participants. Assignment of interventions Randomization Patient numbers (e.g., patients numbered 1–29) will be pre-assigned in advance by a statistician based on the sample size calculation. Participants enrolled in the study will be sequentially assigned numbers according to the order of their visits. The oral mucosal erosive lesions in OLP participants will be divided along the midline into a left and a right side. Through computer-generated randomization, one side will be assigned as the test side and the other will subsequently be designated the control side. The test side will receive periodontal initial therapy under local anesthesia combined with an intralesional BSP injection, while the control side will receive the intralesional BSP injection alone. Due to the nature of the study, blinding of both researchers and participants was not feasible. Consequently, to mitigate potential bias, a rigorous protocol for allocation concealment and blinded outcome assessment will be implemented. Allocation concealment The randomization sequence will be concealed using sealed, opaque envelopes. The allocation will be revealed after baseline assessments. The clinician performing periodontal therapy will open the envelope, who is separate from the outcome assessors. Members of the study staff will not have access to the envelopes prior to assignment. Blinded outcome assessment All outcome assessments were conducted by trained assessors who were strictly blinded to the treatment allocation for each side of the oral cavity. To ensure the integrity of the blinding and to standardize assessments across the five study centers, we will use a centralized, blinded review process (Fig. 3).Image anonymization: At each study center, local coordinator will de-identify all digital scans and clinical photographs. All patient-identifying information and any reference to the treatment side will be removed, leaving only a unique, non-identifiable subject code and visit number. The central data management team will further mask the images by assigning a new random code to each one before sending them to the assessors. This ensured the central assessors had no information linking the images to a specific treatment allocation.Independent central assessment: Two calibrated central assessors will independently evaluate lesion area. In the event of a significant discrepancy between the two assessors’ findings, a third, senior assessor would perform a final adjudication.Protection of the blind: Assessors will not access to any clinical treatment records. Participants will be instructed not to disclose the details of their treatment allocation. Assessments will follow a standardized script that avoids allocation- related questions.Fig. 3Centralized, blinded review process Image anonymization: At each study center, local coordinator will de-identify all digital scans and clinical photographs. All patient-identifying information and any reference to the treatment side will be removed, leaving only a unique, non-identifiable subject code and visit number. The central data management team will further mask the images by assigning a new random code to each one before sending them to the assessors. This ensured the central assessors had no information linking the images to a specific treatment allocation. Image anonymization: At each study center, local coordinator will de-identify all digital scans and clinical photographs. All patient-identifying information and any reference to the treatment side will be removed, leaving only a unique, non-identifiable subject code and visit number. The central data management team will further mask the images by assigning a new random code to each one before sending them to the assessors. This ensured the central assessors had no information linking the images to a specific treatment allocation. Independent central assessment: Two calibrated central assessors will independently evaluate lesion area. In the event of a significant discrepancy between the two assessors’ findings, a third, senior assessor would perform a final adjudication. Independent central assessment: Two calibrated central assessors will independently evaluate lesion area. In the event of a significant discrepancy between the two assessors’ findings, a third, senior assessor would perform a final adjudication. Protection of the blind: Assessors will not access to any clinical treatment records. Participants will be instructed not to disclose the details of their treatment allocation. Assessments will follow a standardized script that avoids allocation- related questions. Protection of the blind: Assessors will not access to any clinical treatment records. Participants will be instructed not to disclose the details of their treatment allocation. Assessments will follow a standardized script that avoids allocation- related questions. Centralized, blinded review process Unblinding situations Procedures for unblinding are defined for two distinct scenarios. First, planned study-wide unblinding will occur only after the final database is locked and all primary statistical analyses are complete. Second, emergency unblinding for an individual participant may be necessary in the event of a Serious Adverse Event (SAE). Data collection, management, and analysis Overview of data collection The primary data will be stored and retrieved at the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. Upon obtaining the original participant data, researchers will store the data via electronic Case Report Forms (eCRFs) in Electronic Data Capture (EDC) systems. Participant names and other identifying details will not be included in any auxiliary study data electronic files. All documents will be securely stored, and access will be restricted to researchers and authorized personnel. Researchers will archive the original documents and informed consent forms for each participant. For each enrolled case, the eCRF must be completed in the EDC system as required. We will utilize the MedCohort EDC system (MedCohort) to collect and manage data from the Hospital Information System. MedCohort, an independently developed clinical research information management platform by the Ninth People’s Hospital affiliated with Shanghai Jiao Tong University School of Medicine, enables the automatic synchronization of highly structured and standardized data, including patients’ diagnostic and therapeutic information, laboratory and imaging results, and follow-up records, during clinical data collection. Data security and submission of monitoring reports Each participant will receive a unique study ID, which will be the sole identifier used on all research data. A master list linking these IDs to personal identifying information will be securely and separately stored by the Site Principal Investigator, with access restricted to designated members of the research team. This ensures that the personnel responsible for statistical analysis will only be provided with a pseudonymized dataset, preventing direct identification of participants during their work. Given the low-risk nature of this study, data security and monitoring reports will be submitted to the Ethics Committee every 12 months. Data retention All researchers must maintain complete clinical records and research data for all participants participating in this study. Intraoral clinical photographs should be archived electronically and securely stored along with participants’ clinical records and research documentation. The study coordinator will collect copies of all electronic files. All study-related records will be retained for at least 5 years after the study’s completion. Statistical analysis Analysis set Analysis populations are defined as follows:Intention to treat (ITT): this population includes all randomized participants regardless of whether they were later found to be ineligible, did not adhere to the protocol or were never treated.Per protocol (PP): this population contains all randomized participants who received their allocated trial treatment without major protocol deviations.Safety population: this population contains all randomized participants who received at least one dose of study intervention and will be classified according to the actual treatment received. Intention to treat (ITT): this population includes all randomized participants regardless of whether they were later found to be ineligible, did not adhere to the protocol or were never treated. Intention to treat (ITT): this population includes all randomized participants regardless of whether they were later found to be ineligible, did not adhere to the protocol or were never treated. Per protocol (PP): this population contains all randomized participants who received their allocated trial treatment without major protocol deviations. Per protocol (PP): this population contains all randomized participants who received their allocated trial treatment without major protocol deviations. Safety population: this population contains all randomized participants who received at least one dose of study intervention and will be classified according to the actual treatment received. Safety population: this population contains all randomized participants who received at least one dose of study intervention and will be classified according to the actual treatment received. The analysis of the primary outcome will be in the ITT population, with sensitivity analysis in the PP population. The safety population will be used to report side effects. Demographic data and analysis Descriptive statistical methods were used to summarize the demographic and clinical characteristics of the study population. Continuous variables were described using mean ± standard deviation or median with interquartile range (IQR), while categorical variables were presented as frequencies. The Kolmogorov–Smirnov (K-S) test was employed to assess whether the clinical indicators at baseline and reevaluation followed a normal distribution. Levene’s test was used to check the homogeneity of variance. Analysis of efficacy outcomes The statistical analysis of efficacy is structured to assess a single primary endpoint at the 12th week, complemented by the analysis of several secondary endpoints at interim time points. Primary efficacy analysis: The primary efficacy endpoint is the reduction in the size of the erosion area (mm2) of the lesion at the 12-week visit. The primary analysis will be conducted by comparing the values between the test side and the control side. A paired t-test or its non-parametric equivalent, the Wilcoxon signed-rank test, will be used for this comparison, with the choice of test based on the assessment of data normality.Secondary efficacy analysis: The interim assessments at 2nd, 4th, 8th, 12th week, and the follow-up assessment at 24th week are designed for the analysis of various secondary outcomes. Specifically, data from these time points will be used to compare the healing rate of oral mucosal erosive lesions between groups (using the chi-squared test or Fisher’s exact test) and to analyze differences in the absolute change from baseline for the patient’s pain VAS score and OLP clinical damage score (using t-tests or Wilcoxon tests). Furthermore, changes in periodontal parameters will be assessed at 4th, 8th, 12th, and 24th week. Throughout this period, all AEs will be recorded and summarized by frequency and incidence rate at each visit to evaluate safety.Supportive longitudinal analysis: To supplement the primary analysis and fully utilize the data collected at interim visits, a supportive analysis using a mixed model for repeated measures will be performed on the primary efficacy endpoint. This model will include all data from baseline, 2nd, 4th, 8th, and 12th week to assess the overall treatment effect trajectory over the primary study period.Observational follow-up data analysis: Data collected during the observational follow-up phase will be analyzed separately using descriptive statistics. The trajectory of lesion changes on the original control side after receiving the intervention will be reported, and the maintenance of the effect on the original test side will be assessed. To avoid confounding bias from the crossover intervention, data from this later phase will not be used for the primary hypothesis testing.Effect sizes for the mean differences between the two groups were measured using Cohen’s d or Hedge’s g (with the following interpretations: Cohen’s d < 0.2: negligible difference; 0.2 ≤ Cohen’s d < 0.5: small difference; 0.5 ≤ Cohen’s d < 0.8: moderate difference; Cohen’s d ≥ 0.8: large difference). The (corrected) Chi-square test or Fisher’s exact test was used to compare the difference in healing rates of oral mucosal erosive lesions between the two groups. Primary efficacy analysis: The primary efficacy endpoint is the reduction in the size of the erosion area (mm2) of the lesion at the 12-week visit. The primary analysis will be conducted by comparing the values between the test side and the control side. A paired t-test or its non-parametric equivalent, the Wilcoxon signed-rank test, will be used for this comparison, with the choice of test based on the assessment of data normality. Primary efficacy analysis: The primary efficacy endpoint is the reduction in the size of the erosion area (mm2) of the lesion at the 12-week visit. The primary analysis will be conducted by comparing the values between the test side and the control side. A paired t-test or its non-parametric equivalent, the Wilcoxon signed-rank test, will be used for this comparison, with the choice of test based on the assessment of data normality. Secondary efficacy analysis: The interim assessments at 2nd, 4th, 8th, 12th week, and the follow-up assessment at 24th week are designed for the analysis of various secondary outcomes. Specifically, data from these time points will be used to compare the healing rate of oral mucosal erosive lesions between groups (using the chi-squared test or Fisher’s exact test) and to analyze differences in the absolute change from baseline for the patient’s pain VAS score and OLP clinical damage score (using t-tests or Wilcoxon tests). Furthermore, changes in periodontal parameters will be assessed at 4th, 8th, 12th, and 24th week. Throughout this period, all AEs will be recorded and summarized by frequency and incidence rate at each visit to evaluate safety. Secondary efficacy analysis: The interim assessments at 2nd, 4th, 8th, 12th week, and the follow-up assessment at 24th week are designed for the analysis of various secondary outcomes. Specifically, data from these time points will be used to compare the healing rate of oral mucosal erosive lesions between groups (using the chi-squared test or Fisher’s exact test) and to analyze differences in the absolute change from baseline for the patient’s pain VAS score and OLP clinical damage score (using t-tests or Wilcoxon tests). Furthermore, changes in periodontal parameters will be assessed at 4th, 8th, 12th, and 24th week. Throughout this period, all AEs will be recorded and summarized by frequency and incidence rate at each visit to evaluate safety. Supportive longitudinal analysis: To supplement the primary analysis and fully utilize the data collected at interim visits, a supportive analysis using a mixed model for repeated measures will be performed on the primary efficacy endpoint. This model will include all data from baseline, 2nd, 4th, 8th, and 12th week to assess the overall treatment effect trajectory over the primary study period. Supportive longitudinal analysis: To supplement the primary analysis and fully utilize the data collected at interim visits, a supportive analysis using a mixed model for repeated measures will be performed on the primary efficacy endpoint. This model will include all data from baseline, 2nd, 4th, 8th, and 12th week to assess the overall treatment effect trajectory over the primary study period. Observational follow-up data analysis: Data collected during the observational follow-up phase will be analyzed separately using descriptive statistics. The trajectory of lesion changes on the original control side after receiving the intervention will be reported, and the maintenance of the effect on the original test side will be assessed. To avoid confounding bias from the crossover intervention, data from this later phase will not be used for the primary hypothesis testing. Observational follow-up data analysis: Data collected during the observational follow-up phase will be analyzed separately using descriptive statistics. The trajectory of lesion changes on the original control side after receiving the intervention will be reported, and the maintenance of the effect on the original test side will be assessed. To avoid confounding bias from the crossover intervention, data from this later phase will not be used for the primary hypothesis testing. Effect sizes for the mean differences between the two groups were measured using Cohen’s d or Hedge’s g (with the following interpretations: Cohen’s d < 0.2: negligible difference; 0.2 ≤ Cohen’s d < 0.5: small difference; 0.5 ≤ Cohen’s d < 0.8: moderate difference; Cohen’s d ≥ 0.8: large difference). The (corrected) Chi-square test or Fisher’s exact test was used to compare the difference in healing rates of oral mucosal erosive lesions between the two groups. Effect sizes for the mean differences between the two groups were measured using Cohen’s d or Hedge’s g (with the following interpretations: Cohen’s d < 0.2: negligible difference; 0.2 ≤ Cohen’s d < 0.5: small difference; 0.5 ≤ Cohen’s d < 0.8: moderate difference; Cohen’s d ≥ 0.8: large difference). The (corrected) Chi-square test or Fisher’s exact test was used to compare the difference in healing rates of oral mucosal erosive lesions between the two groups. Sensitivity analyses To evaluate the robustness of the primary outcome, a series of sensitivity analyses will be conducted. The main analysis will be supplemented with a multivariate linear regression to adjust for potential confounding variables (age, gender, baseline erosion area, periodontitis stage, baseline VAS score, smoking history, systemic medical history, and concomitant medications), and a repeated-measures mixed-effects model will assess the dynamic effect of the intervention. Furthermore, to robustly handle missing data and minimize potential bias, a key sensitivity analysis will be performed using multiple imputation. Additional analyses will include repeating the primary model on the PPS and assessing the potential influence of the study center. Statistical software and general requirements Primary efficacy analysis in this study is one-tailed, with P < 0.025 considered statistically significant. For all other secondary and exploratory outcomes, we will use two-sided tests, with statistical significance set at P < 0.05. Statistical analyses and graphical representations will be performed using SPSS version 25.0 (Armonk, NY, USA: IBM Corp.). Monitoring This multi-center trial will be managed by a structured framework involving a coordinating center, participating sites, and dedicated committees to ensure protocol adherence, data integrity, and uniform conduct across all locations. Coordinating center and principal investigator (PI) The study is coordinated by the Ninth People’s Hospital affiliated with Shanghai Jiao Tong University School of Medicine, which acts as the Coordinating Center. The PI at this center holds the ultimate responsibility for the entire trial. Participating centers and co-investigators Each participating hospital will have a designated co-investigator. They are responsible for the day-to-day conduct of the trial at their specific centers, including participant recruitment and enrollment, adherence to the protocol, local data collection, and timely reporting of AEs to the coordinating center. Steering committee (SC) The SC will be chaired by the PI and will include co-investigators from the participating centers. A trial statistician will also be included. The SC will meet quarterly to oversee the overall conduct and progress of the trial. Its key responsibilities include: monitoring recruitment rates; ensuring adherence to the study protocol across all sites; reviewing safety data; and approving any proposed amendments to the protocol before they are submitted to the Ethics Committees. Endpoint adjudication committee (EAC) To ensure unbiased and standardized evaluation of the primary endpoint, an independent EAC will be established. The EAC will consist of two experienced clinicians with expertise in oral medicine who are independent of the trial. Data management team A central Data Management Team, based at the coordinating center and led by the PI and Clinical Research Coordinator (CRC), will oversee all data-related activities. This team is responsible for designing and maintaining the central eCRF, performing data validation and quality checks on data submitted from all centers. The CRC will review the eCRFs of the first few participants from each site to ensure accuracy and completeness. Independent oversight Researchers who have received Good Clinical Practice–related training will conduct regular monitoring, including on-site visits. This involves the review of source documents, clinical records, and informed consent forms to ensure data quality and compliance with the protocol. The protocol is approved by the lead Ethics Committee of the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, and subsequently by the local Ethics Committee of each participating center. The trial will also be supervised by the National Clinical Research Center for Oral Diseases. Data monitoring committee (DMC) A formal DMC is not deemed necessary for this study due to its low-risk profile. Given the minimal anticipated risks, the study duration is limited, and the endpoints do not involve severe morbidity or mortality. Safety oversight, including the review of all adverse events, will be managed directly by the SC. They will report any significant findings to the IRB/REC as required. Discussion This study protocol proposes a randomized, self-controlled trial to evaluate a novel therapeutic strategy for erosive OLP. While previous studies have examined the benefits of periodontal care for gingival OLP, to our knowledge, no randomized controlled trial has specifically integrated periodontal initial therapy under local anesthesia with corticosteroid injections for the more challenging erosive form of the disease. Therefore, this trial is designed to fill a critical gap in the literature by addressing a key treatment barrier. The core novelty of our approach lies in combining periodontal initial therapy under local anesthesia with intralesional corticosteroid injections simultaneously. This design directly addresses a critical clinical challenge: the pain that prevents erosive OLP patients from receiving necessary periodontal care. Our central hypothesis is that by interrupting the “vicious cycle” where OLP-related pain hinders oral hygiene, leading to plaque accumulation and exacerbated periodontal inflammation that in turn worsens OLP lesions and delays erosion healing, we can significantly improve both mucosal and periodontal outcomes. This study aims to provide high-quality evidence for a more comprehensive, patient-centered treatment model. The mechanistic justification for this integrated approach is compelling, though not yet fully elucidated. It is well established that dental plaque biofilm, harboring periodontopathogens like Porphyromonas gingivalis, serves as a constant inflammatory trigger [20, 21]. We postulate that the resulting bacterial toxins and pro-inflammatory cytokines contribute directly to the inflammatory microenvironment of adjacent OLP lesions, perpetuating the disease state. Therefore, by mechanically removing this microbial load through scaling and root planing, made tolerable for patients via local anesthesia, our intervention is expected to down-regulate local inflammatory pathways, potentially reducing OLP lesion severity and pain. This aligns with previous findings where basic periodontal care improved outcomes in gingival OLP [10, 22], but our study advances this by targeting the more challenging erosive OLP population and using a more rigorous design. The study has several strengths that contribute to its significance. The randomized, self-controlled design served to minimize inter-individual variability and thus enhance the reliability of the findings. A comprehensive range of outcome measures was employed, including objective assessments of erosive lesion size, pain scores, and periodontal clinical parameters, thereby providing a robust evaluation of the intervention’s efficacy. Moreover, the utilization of sophisticated instruments, such as digital intraoral scanners, is intended to enhance the precision and reproducibility of measurements, thereby strengthening the methodological rigor. Additionally, the use of the EDC system streamlines data collection and management, ensures accurate, real-time recording of patient information while minimizing information bias. This facilitates efficient data monitoring and improved data integrity throughout the study, further strengthening the validity of the results. While the study protocol integrated key ethical safeguards reflecting a patient-centric approach (primarily by using local anesthesia to mitigate procedural risk and discomfort), it must be acknowledged that there are notable limitations which require consideration. The first limitation of the study is that the 12-week follow-up period may not fully capture the long-term benefits or recurrence rates of the combined therapy. While the multicenter design strengthens the generalizability of the results, the sample size remains relatively small, which could still limit the broader applicability of the findings. Additionally, the exclusion of patients with severe erosive OLP or systemic conditions, while necessary for protocol adherence, restricts the generalizability of the results to these specific subgroups. The split-mouth design, while accounting for patient variability, poses a risk of a “carry-across effect” from systemic or salivary mediators. Although prior clinical outcomes indicate this effect may be minimal, it is not formally excluded through biomarker analysis. Future research should therefore utilize larger cohorts, longer follow-up periods, and biomarker analysis to address these constraints, with the goal of validating the findings across more diverse populations. In conclusion, this protocol provides an innovative approach to the management of erosive OLP with co-occurring periodontitis. By focusing on breaking a critical inflammatory cycle through a patient-centric design, this study is expected to provide significant contributions. Its primary significance lies in its potential to establish a more effective, multidisciplinary treatment standard that may reduce patient discomfort and improve long-term compliance. Based on the clinical evidence from this trial, future molecular mechanistic studies could explore the biological mechanisms underlying the clinical improvements. These studies are expected to reveal the unique immune regulatory patterns in the inflammatory microenvironment of OLP with periodontitis. Trial status The protocol described is dated 09/01/2025 (version 1). The first participant will be recruited to the study on 10/01/2025. Recruitment will be anticipated to be completed by May 2026. Supplementary Information Supplementary Material 1. SPIRIT checklist.Supplementary Material 2. Supplementary Material 1. SPIRIT checklist. Supplementary Material 2.